The San Diego Biotech Survival Index: Local Firms Make Strong Rebound In First Half of 2009

9/23/09Follow @xconomy

(Page 2 of 4)

Ardea Biosciences (NASDAQ: RDEA)
Cash on hand: $70.1 million
Previous Xconomy coverage:
Ardea, Developer of Gout Drug, Sees Early Signs of Effectiveness
Ardea Biosciences, In Moment of Serendipity, Discovers HIV Drug That May Work for Gout

Arena Pharmaceuticals (NASDAQ: ARNA)
Cash on hand: $39.6 million
Previous Xconomy coverage:
Arena Eagerly Awaits Answer to $1 Billion Question: Does It Have a Big-Time Obesity Drug?
Arena Obesity Drug Helps Patients Shed a Few Pounds, Lower Risk of Heart Disease
Arena Drug Passes Second Trial, Aims to Sell Safe Option for Millions of People

Cadence Pharmaceuticals (NASDAQ: CADX)
Cash on hand: $105.4 million
Previous Xconomy coverage:
Cadence Turns Attention to Marketplace as IV Pain Reliever Reaches Goals in Clinical Trials
Cadence, Aiming to Reduce Narcotics Use in Hospitals, Gears Up to Market IV Pain Reliever

Cypress Bioscience (NASDAQ: CYPB)
Cash on hand: $151.3 million
Previous Xconomy coverage:
Cypress Bioscience, Developer of Fibromyalgia Drug, Eagerly Awaits FDA Deadline
Cypress Bioscience Shares Soar on News of FDA Approval

Cytori Therapeutics (NASDAQ: CYTX)
Cash on hand: $13.9 million
Previous Xconomy coverage:
San Diego’s Cytori Gains Cash, Loses a Patent
Cytori Expands GE Partnership, Raises More Cash
Cytori Raises $10 Million

To purchase a much expanded version of this report, in PDF format, click the “Add to Cart” button.
For $95,* you’ll get an assessment of each company’s financial position at the end of June compared to six months earlier, the projected length of time it can survive on its existing cash reserves, and an analysis of the strategic moves it has made to stay afloat in the current environment. Click here to see a sample entry. Add to Cart
*Price is subject to change without notice.

Gen-Probe (NASDAQ: GPRO)
Cash on hand: $464.2 million
Previous Xconomy coverage:
Gen-Probe Spins Off New Company, Roka Bioscience, for Industrial Testing
Gen-Probe Amends Deal to Get Promising Test for Prostate Cancer

Genoptix Medical (NASDAQ: GXDX)
Cash on hand: $126.7 million
Previous Xconomy coverage:
Riding a Cancer Diagnostics Wave, Genoptix Sees Boom Continuing in 2009

Halozyme Therapeutics (NASDAQ: HALO)
Cash on hand: $89.2 million
Previous Xconomy coverage:
Halozyme Set for Secondary Offering
… Next Page »

Single Page Currently on Page: 1 2 3 4 previous page

By posting a comment, you agree to our terms and conditions.